Navigation Links
Kinex Pharmaceuticals To Present at ASCO 2009 Annual Meeting
Date:5/27/2009

BUFFALO, N.Y., May 27 /PRNewswire/ -- Kinex Pharmaceuticals will present results from a Phase 1 clinical study with KX2-391, at the ASCO 2009 Annual Meeting in Orlando, on May 29, 2009. The study was carried out at MD Anderson, Roswell Park Cancer Institute (RPCI) and Fox Chase Cancer Center. Dr. Alex Adjei, the Principal Investigator from RPCI will deliver the presentation entitled "Results of a phase I trial of KX2-391, a novel non-ATP competitive substrate-pocket directed SRC inhibitor, in patients with advanced malignancies."

The presentation will provide data from this multi-center Phase 1 trial that utilized the standard 3+3 design to determine the Maximum Tolerated Dose (MTD), safety, and pharmacokinetics (PK) of KX2-391 in patients with refractory solid tumors. Patients who responded to treatment will be highlighted.

This presentation was designated as Best of ASCO(R) which features high-impact abstracts from the 2009 ASCO Annual Meeting that represent the most relevant, cutting-edge science in oncology today. This information has been selected to be presented at meetings in the US and internationally because it highlights the latest scientific findings in primary disease sites and practice-changing advances in cancer prevention and treatment.

Kinex Pharmaceuticals is a drug discovery and development company that is focused on next generation drugs to treat cancer and immuno-inflammatory diseases. The Company has utilized its platform technologies to identify highly selective inhibitors of therapeutically relevant targets that are involved in signal transduction and cell cycle control.

CONTACT: Lyn Dyster, Vice President, Research Operations of Kinex Pharmaceuticals, +1-716-881-8984


'/>"/>
SOURCE Kinex Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2015)... Research and Markets ( http://www.researchandmarkets.com/research/t63pbj/medical_device ) has announced the ... Markets Seminar" conference to their offering. ... well established, the next growth area is ... with other countries in this region have all implemented, ... medical device regulations. This seminar will provide a comprehensive ...
(Date:7/27/2015)... and MENLO PARK, Calif. ... Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and the ... commercializing proven cancer therapies in new orphan drug ... from institutional and accredited investors for a registered ... common stock and 3.35 million common stock purchase ...
(Date:7/27/2015)... , July 27, 2015  Cardica, Inc. (Nasdaq: CRDC ... its fiscal fourth quarter ended June 30, 2015, on Thursday, ... host a conference call at 4:30 p.m. Eastern Time to ... company,s business. Conference Call Details To access ... p.m. Eastern Time via phone, please dial 877-703-6106 from ...
Breaking Medicine Technology:Medical Device Regulation in Asia/Pacific Markets Seminar: London, UK - 21st, 22nd of September 2015 2DelMar Pharmaceuticals Announces Financing Update and Initial Subscriptions of $2.0 million in Registered Direct Offering 2DelMar Pharmaceuticals Announces Financing Update and Initial Subscriptions of $2.0 million in Registered Direct Offering 3Cardica To Announce Fiscal 2015 Fourth Quarter Financial Results On Thursday, August 6, 2015 2
... the makers of Cold-EEZE® Cold Remedy , has ... Your Cause Not Your Cold" Campaign. The contest, which sheds ... communities, has awarded each of LuLu,s Rescue of Point Pleasant, ... Mentor, OH with $1,000 to assist with their respective missions ...
... COLUMBUS, Ohio and FLORHAM PARK, N.J., Jan. 26, ... Homecare Solutions announced today a joint development and ... within Definitive Homecare,s CPR+ specialty pharmacy software. Armada ... organization for specialty pharmacies, providing services such as ...
Cached Medicine Technology:Cold-EEZE® Cold Remedy Announces Winners in its "Share Your Cause Not Your Cold" Campaign 2Cold-EEZE® Cold Remedy Announces Winners in its "Share Your Cause Not Your Cold" Campaign 3Cold-EEZE® Cold Remedy Announces Winners in its "Share Your Cause Not Your Cold" Campaign 4Armada Health Care and Definitive Homecare Solutions Announce Alliance for Specialty Pharmacy Software and Services 2Armada Health Care and Definitive Homecare Solutions Announce Alliance for Specialty Pharmacy Software and Services 3
(Date:7/27/2015)... (PRWEB) , ... July 27, 2015 , ... Eugene Batelli, ... an accomplished athlete. “The patient is high-end athlete, whose accomplishments include running in ... months of Achilles tendon pain, which was diagnosed as tendinitis. I did an ...
(Date:7/27/2015)... ... 27, 2015 , ... The Maricopa Community Colleges today announced a ... system to get into and complete college. , The “Bridging Success Initiative,” funded ... today with partners from across the valley. , The initiative advisory board has representatives ...
(Date:7/27/2015)... ... July 27, 2015 , ... David Gilmour ... will be performing for one additional night at each of his original four tour ... for added savings. , David Gilmour’s 2016 North America tour dates: , Thursday, March ...
(Date:7/27/2015)... (PRWEB) , ... July 27, ... ... on Global Calcium Propionate industry is a professional and in-depth research report. ... overview, industry chain structure, international market analysis etc. This report covers the ...
(Date:7/27/2015)... Chico, CA (PRWEB) , ... July 27, 2015 , ... ... has teamed up with PursuitSAFETY to support its mission of reducing the number of ... funds to help support victims and their families. PursuitSAFETY works with the police ...
Breaking Medicine News(10 mins):Health News:NJ Top Docs Presents, Dr. Eugene Batelli of Metropolitan Ankle & Foot Care Specialists 2Health News:NJ Top Docs Presents, Dr. Eugene Batelli of Metropolitan Ankle & Foot Care Specialists 3Health News:Maricopa Community Colleges Launch Program To Help Youth In Foster Care Finish College 2Health News:Maricopa Community Colleges Launch Program To Help Youth In Foster Care Finish College 3Health News:Cheap David Gilmour Tickets at Madison Square Garden (MSG), Air Canada Center, United Center and Hollywood Bowl: Additional Dates for David Gilmour Go On Sale Today 2Health News:Calcium Propionate Market Global Suppliers and Manufacture Analysis 2Health News:Calcium Propionate Market Global Suppliers and Manufacture Analysis 3Health News:Gary Short & Associates in Chico, CA Initiates Charity Campaign to Collaborate with National Nonprofit PursuitSAFETY 2Health News:Gary Short & Associates in Chico, CA Initiates Charity Campaign to Collaborate with National Nonprofit PursuitSAFETY 3
... fatal diseases –sleeping sickness, leishmaniasis //and Chagas disease that ... cruzi. The three diseases have mostly been to affect ... affect about half a billion people worldwide and claim ... by National Institute of Allergy and Infectious Diseases (NIAID) ...
... maintained by the health workers may cause as much as ... ,Researchers from University of Illinois had reported that more ... the health workers that cause the erratic nature of health ... the health care systems. The report said that the number ...
... Ruboxistaurin (RBX) at a concentration of 32 milligrams/day// was found ... was found to cause vision loss in patients with diabetes. ... with type 1 or type 2 diabetes by the Research ... Netherlands and United Kingdom. The study was named as PKS-DRS, ...
... activities in teenage girls is to be blamed as the ... who remain inactive during their adolescence tend to gain more ... physical activity during their teens. In a ten year observational ... that the rapid decline in the physical activities by the ...
... skin patches (brand name Duragesic) a potent narcotic medication for ... in patients using the patch were reported. The FDA says ... these patches as it is unclear if the deaths are ... to the quality of the product. ,Deaths and overdoses ...
... people are reluctant to accept kidney donors// unless they ... to donors a stusy form Cardiff University research has ... Nursing and Midwifery Studies recruited 11 kidney donors and ... ,After interviewing them about their experiences of the process, ...
Cached Medicine News:Health News:Three Tropical Parasites Genetic Code Unravelled 2
The Shandon Cryotome E Cryostat model features an automated, precise electronic specimen advance system....
The Shandon Pathcentre is a high-volume, totally enclosed tissue processor that allows complete user control and excellent continuous reagent agitation....
... Shandon Excelsior Tissue Processor is ... using traditional reagents today. It ... outstanding features to provide benefits ... increased productivity, reagent cost savings ...
The Shandon Grosslab Grossing Workstation comes in a bench top or stand alone design for the gross examination and sectioning of specimens....
Medicine Products: